



Press release from Emotra AB (publ)  
Göteborg, December 21, 2020

## Our first study on the risk of depression relapse has been accepted for publication

**Today, Emotra is proud to announce that a manuscript that reports the findings from our first study on the connection between hyporeactivity and increased risk of depression relapse has been accepted for publication in the scientific journal BMC Psychiatry.**

BMC Psychiatry has notified us that the following manuscript has been accepted for publication: *“Clinical effectiveness of the electrodermal orienting reactivity test for evaluating relapse and recurrence risk in patients hospitalized for depression”*.

This paper was written by Marta Litwinska, Toomas Timpka and Armin Spreco, and describes the use of EDOR on in-patients to study the connection between hyporeactivity and the risk of depression relapse. The results, which are based on testing and follow-up of about 100 patients, show that hyporeactive patients run a greater risk of depression relapse.

These results will now need to be confirmed in a larger, multi-centre study, which we plan on launching in 2021, on condition that the current Corona pandemic will allow it.

### **Daniel Poté, Emotra’s CEO, has the following comment:**

*“First of all, I would like to take this opportunity to thank the authors for the work they have put into this manuscript. This is a welcome and important step for Emotra and the company’s clinical development that will facilitate our present and future marketing contacts. The company is now embarking on a scientific journey where the path ahead of us is based on data and publications. In this effort, our study, to quote BMC’s editors’ note to the authors, is ‘a valuable first step for future research in this area.’”*

**For further information, please contact:** Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

---

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

EMOTRA AB, AstraZeneca BioVentureHub, Pepparedsleden 1  
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)